Cargando…

Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination

Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 vaccination. To investigate this observation, a prospective single-institution study was conducted comparing peripheral blood monon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye Kyung, Hoechstetter, Manuela A., Buchner, Maike, Pham, Trang Thu, Huh, Jin Won, Müller, Katharina, Zange, Sabine, von Buttlar, Heiner, Girl, Philipp, Wölfel, Roman, Brandmeier, Lisa, Pfeuffer, Lisa, Furth, Priscilla A., Wendtner, Clemens-Martin, Hennighausen, Lothar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906673/
https://www.ncbi.nlm.nih.gov/pubmed/36630562
http://dx.doi.org/10.1182/bloodadvances.2022008445
_version_ 1784884029621796864
author Lee, Hye Kyung
Hoechstetter, Manuela A.
Buchner, Maike
Pham, Trang Thu
Huh, Jin Won
Müller, Katharina
Zange, Sabine
von Buttlar, Heiner
Girl, Philipp
Wölfel, Roman
Brandmeier, Lisa
Pfeuffer, Lisa
Furth, Priscilla A.
Wendtner, Clemens-Martin
Hennighausen, Lothar
author_facet Lee, Hye Kyung
Hoechstetter, Manuela A.
Buchner, Maike
Pham, Trang Thu
Huh, Jin Won
Müller, Katharina
Zange, Sabine
von Buttlar, Heiner
Girl, Philipp
Wölfel, Roman
Brandmeier, Lisa
Pfeuffer, Lisa
Furth, Priscilla A.
Wendtner, Clemens-Martin
Hennighausen, Lothar
author_sort Lee, Hye Kyung
collection PubMed
description Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 vaccination. To investigate this observation, a prospective single-institution study was conducted comparing peripheral blood mononuclear cell transcriptional response with antibody and T-cell response rates following heterologous BNT162b2/ChAdOx1 vaccination of 15 patients with CLL/small lymphocytic lymphoma (SLL). Two-dose antibody response rate was 40%, increasing to 53% after booster. Patients on Bruton tyrosine kinase inhibitor (BTKi) and venetoclax ± anti-CD20 antibody within 12 months of vaccination responded inferiorly compared with those under BTKi alone. The 2-dose–T-cell response rate was 80%, which increased to 93% after the booster dose. Key transcriptional findings were that interferon–mediated signaling activation including activation of the JAK-STAT pathway generally occurred within days of vaccination, but was independent from the magnitude of the antibody response. Increasing counts of IGHV genes were associated with B-cell reconstitution and improved humoral response rate in the vaccinated patients. T-cell responses in patients with CLL appeared independent of treatment status, whereas higher humoral response rate was associated with BTKi treatment and B-cell reconstitution. Boosting was particularly effective when intrinsic immune status was improved by CLL treatment. Limitations included studying a relatively small cohort, with different treatments and vaccination schedules.
format Online
Article
Text
id pubmed-9906673
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-99066732023-02-08 Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination Lee, Hye Kyung Hoechstetter, Manuela A. Buchner, Maike Pham, Trang Thu Huh, Jin Won Müller, Katharina Zange, Sabine von Buttlar, Heiner Girl, Philipp Wölfel, Roman Brandmeier, Lisa Pfeuffer, Lisa Furth, Priscilla A. Wendtner, Clemens-Martin Hennighausen, Lothar Blood Adv Immunobiology and Immunotherapy Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 vaccination. To investigate this observation, a prospective single-institution study was conducted comparing peripheral blood mononuclear cell transcriptional response with antibody and T-cell response rates following heterologous BNT162b2/ChAdOx1 vaccination of 15 patients with CLL/small lymphocytic lymphoma (SLL). Two-dose antibody response rate was 40%, increasing to 53% after booster. Patients on Bruton tyrosine kinase inhibitor (BTKi) and venetoclax ± anti-CD20 antibody within 12 months of vaccination responded inferiorly compared with those under BTKi alone. The 2-dose–T-cell response rate was 80%, which increased to 93% after the booster dose. Key transcriptional findings were that interferon–mediated signaling activation including activation of the JAK-STAT pathway generally occurred within days of vaccination, but was independent from the magnitude of the antibody response. Increasing counts of IGHV genes were associated with B-cell reconstitution and improved humoral response rate in the vaccinated patients. T-cell responses in patients with CLL appeared independent of treatment status, whereas higher humoral response rate was associated with BTKi treatment and B-cell reconstitution. Boosting was particularly effective when intrinsic immune status was improved by CLL treatment. Limitations included studying a relatively small cohort, with different treatments and vaccination schedules. The American Society of Hematology 2023-01-13 /pmc/articles/PMC9906673/ /pubmed/36630562 http://dx.doi.org/10.1182/bloodadvances.2022008445 Text en Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Immunobiology and Immunotherapy
Lee, Hye Kyung
Hoechstetter, Manuela A.
Buchner, Maike
Pham, Trang Thu
Huh, Jin Won
Müller, Katharina
Zange, Sabine
von Buttlar, Heiner
Girl, Philipp
Wölfel, Roman
Brandmeier, Lisa
Pfeuffer, Lisa
Furth, Priscilla A.
Wendtner, Clemens-Martin
Hennighausen, Lothar
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title_full Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title_fullStr Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title_full_unstemmed Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title_short Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
title_sort analysis of immune responses in patients with cll after heterologous covid-19 vaccination
topic Immunobiology and Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906673/
https://www.ncbi.nlm.nih.gov/pubmed/36630562
http://dx.doi.org/10.1182/bloodadvances.2022008445
work_keys_str_mv AT leehyekyung analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT hoechstettermanuelaa analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT buchnermaike analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT phamtrangthu analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT huhjinwon analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT mullerkatharina analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT zangesabine analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT vonbuttlarheiner analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT girlphilipp analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT wolfelroman analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT brandmeierlisa analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT pfeufferlisa analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT furthpriscillaa analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT wendtnerclemensmartin analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination
AT hennighausenlothar analysisofimmuneresponsesinpatientswithcllafterheterologouscovid19vaccination